{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:44:10Z","timestamp":1789343050697,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T00:00:00Z","timestamp":1343001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The advanced phases of chronic myeloid leukemia (CML) are known to be more resistant to therapy. This resistance has been associated with the overexpression of<jats:italic>ABCB1<\/jats:italic>, which gives rise to the multidrug resistance (MDR) phenomenon. MDR is characterized by resistance to nonrelated drugs, and P-glycoprotein (encoded by<jats:italic>ABCB1<\/jats:italic>) has been implicated as the major cause of its emergence. Wnt signaling has been demonstrated to be important in several aspects of CML. Recently, Wnt signaling was linked to<jats:italic>ABCB1<\/jats:italic>regulation through its canonical pathway, which is mediated by \u03b2-catenin, in other types of cancer. In this study, we investigated the involvement of the Wnt\/\u03b2-catenin pathway in the regulation of<jats:italic>ABCB1<\/jats:italic>transcription in CML, as the basal promoter of<jats:italic>ABCB1<\/jats:italic>has several \u03b2-catenin binding sites. \u03b2-catenin is the mediator of canonical Wnt signaling, which is important for CML progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this work we used the K562 cell line and its derived MDR-resistant cell line Lucena (K562\/VCR) as CML study models. Real time PCR (RT-qPCR), electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), flow cytometry (FACS), western blot, immunofluorescence, RNA knockdown (siRNA) and Luciferase reporter approaches were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>\u03b2-catenin was present in the protein complex on the basal promoter of<jats:italic>ABCB1<\/jats:italic>in both cell lines<jats:italic>in vitro<\/jats:italic>, but its binding was more pronounced in the resistant cell line<jats:italic>in vivo<\/jats:italic>. Lucena cells also exhibited higher \u03b2-catenin levels compared to its parental cell line.<jats:italic>Wnt1<\/jats:italic>and<jats:italic>\u03b2-catenin<\/jats:italic>depletion and overexpression of nuclear \u03b2-catenin, together with TCF binding sites activation demonstrated that<jats:italic>ABCB1<\/jats:italic>is positively regulated by the canonical pathway of Wnt signaling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results suggest, for the first time, that the Wnt\/\u03b2-catenin pathway regulates<jats:italic>ABCB1<\/jats:italic>in CML.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2407-12-303","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T08:14:02Z","timestamp":1343031242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Wnt\/\u03b2-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia"],"prefix":"10.1186","volume":"12","author":[{"given":"Stephany","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Binato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Du Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgana TL","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Pizzatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Abdelhay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,23]]},"reference":[{"key":"3565_CR1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007, 21: 926-935.","journal-title":"Leukemia"},{"key":"3565_CR2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1042\/BST0351347","volume":"35","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen HG, Holyoake TL: Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans. 2007, 35: 1347-1351. 10.1042\/BST0351347.","journal-title":"Biochem Soc Trans"},{"key":"3565_CR3","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006, 103: 2794-2799. 10.1073\/pnas.0510423103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3565_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007, 12: 528-541. 10.1016\/j.ccr.2007.11.003.","journal-title":"Cancer Cell"},{"key":"3565_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/leu.2010.143","volume":"24","author":"Y Chen","year":"2010","unstructured":"Chen Y, Peng C, Sullivan C, Li D, Li S: Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010, 24: 1545-1554. 10.1038\/leu.2010.143.","journal-title":"Leukemia"},{"key":"3565_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.stem.2007.11.006","volume":"1","author":"AJ Deshpande","year":"2007","unstructured":"Deshpande AJ, Buske C: Knocking the Wnt out of the sails of leukemia stem cell development. Cell Stem Cell. 2007, 1: 597-598. 10.1016\/j.stem.2007.11.006.","journal-title":"Cell Stem Cell"},{"key":"3565_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/leu.2008.262","volume":"23","author":"Y Hu","year":"2009","unstructured":"Hu Y, Chen Y, Douglas L, Li S: beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009, 23: 109-116. 10.1038\/leu.2008.262.","journal-title":"Leukemia"},{"key":"3565_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/annonc\/mdl273","volume":"17","author":"A Hochhaus","year":"2006","unstructured":"Hochhaus A: Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Ann Oncol. 2006, 17: 274-279. 10.1093\/annonc\/mdl273.","journal-title":"Ann Oncol"},{"key":"3565_CR9","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.3816\/CLM.2007.s.006","volume":"7","author":"TI Mughal","year":"2007","unstructured":"Mughal TI, Goldman JM: Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. Clin Lymphoma Myeloma. 2007, 7: S81-S84.","journal-title":"Clin Lymphoma Myeloma"},{"key":"3565_CR10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE: Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. Cancer Control. 2009, 16: 122-131.","journal-title":"Cancer Control"},{"key":"3565_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7696(05)46001-5","volume":"246","author":"AA Shtil","year":"2005","unstructured":"Shtil AA, Azare J: Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int Rev Cytol. 2005, 246: 1-29.","journal-title":"Int Rev Cytol"},{"key":"3565_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0006-2952(02)01156-5","volume":"64","author":"S Labialle","year":"2002","unstructured":"Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG: Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol. 2002, 64: 943-948. 10.1016\/S0006-2952(02)01156-5.","journal-title":"Biochem Pharmacol"},{"key":"3565_CR13","first-page":"4761","volume":"60","author":"T Yamada","year":"2000","unstructured":"Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S: Transactivation of the multidrug resistance 1 gene by T-cell factor 4\/beta-catenin complex in early colorectal carcinogenesis. Cancer Res. 2000, 60: 4761-4766.","journal-title":"Cancer Res"},{"key":"3565_CR14","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/onc.2009.80","volume":"28","author":"M Flahaut","year":"2009","unstructured":"Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph JM, M\u00fchlethaler-Mottet A, Gross N: The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt\/beta-catenin pathway. Oncogene. 2009, 28: 2245-2256. 10.1038\/onc.2009.80.","journal-title":"Oncogene"},{"key":"3565_CR15","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1074\/jbc.M806708200","volume":"284","author":"LYW Bourguignon","year":"2009","unstructured":"Bourguignon LYW, Xia W, Wong G: Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem. 2009, 284: 2657-2671.","journal-title":"J Biol Chem"},{"key":"3565_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","volume":"82","author":"H Gurney","year":"2007","unstructured":"Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N: Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 2007, 82: 33-40. 10.1038\/sj.clpt.6100201.","journal-title":"Clin Pharmacol Ther"},{"key":"3565_CR17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","volume":"112","author":"S Dulucq","year":"2008","unstructured":"Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008, 112: 2024-2027. 10.1182\/blood-2008-03-147744.","journal-title":"Blood"},{"key":"3565_CR18","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH: Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009, 15: 4750-4758. 10.1158\/1078-0432.CCR-09-0145.","journal-title":"Clin Cancer Res"},{"key":"3565_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","volume":"28","author":"LN Ni","year":"2011","unstructured":"Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, Qian SX: Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011, 28: 265-269. 10.1007\/s12032-010-9456-9.","journal-title":"Med Oncol"},{"key":"3565_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","volume":"35","author":"M Maffiolia","year":"2011","unstructured":"Maffiolia M, Cam\u00f3sa M, Gayaa A, Hern\u00e1ndez-Boludab JC, \u00c1lvarez-Larr\u00e1nc A, Domingoa A, Granella M, Guillemb V, Vallansota R, Costad D, Bellosillo B, Colomerd D, Cervantesa F: Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res. 2011, 35: 1014-1019. 10.1016\/j.leukres.2010.12.004.","journal-title":"Leuk Res"},{"key":"3565_CR21","first-page":"244","volume":"33","author":"Y Yamakawa","year":"2011","unstructured":"Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H: Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia. Ther Drug Monit. 2011, 33: 244-250.","journal-title":"Ther Drug Monit"},{"key":"3565_CR22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912","volume":"100","author":"AF List","year":"2002","unstructured":"List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR: Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood. 2002, 100: 1910-1912.","journal-title":"Blood"},{"key":"3565_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1134\/S0006297908010045","volume":"73","author":"TP Stromskaya","year":"2008","unstructured":"Stromskaya TP, Rybalkina EY, Kruglov SS, Zabotina TN, Mechetner EB, Turkina AG, Stavrovskaya AA: Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochemistry (Mosc). 2008, 73: 29-37. 10.1134\/S0006297908010045.","journal-title":"Biochemistry (Mosc)"},{"key":"3565_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cyto.b.20580","volume":"80","author":"FC Vasconcelos","year":"2011","unstructured":"Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE, Maia RC: Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom. 2011, 80: 158-166.","journal-title":"Cytometry B Clin Cytom"},{"key":"3565_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/10428194.2010.533220","volume":"52","author":"Z Racil","year":"2011","unstructured":"Racil Z, Razga F, Polakova KM, Buresova L, Polivkova V, Dvorakova D, Zackova D, Klamova H, Cetkovsky P, Mayer J: Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. Leuk Lymphoma. 2011, 52: 331-334. 10.3109\/10428194.2010.533220.","journal-title":"Leuk Lymphoma"},{"key":"3565_CR26","first-page":"471","volume":"26","author":"FR Reis","year":"2011","unstructured":"Reis FR, Vasconcelos FC, Pereira DL, Moellman-Coelho A, Silva KL, Maia RC: Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep. 2011, 26: 471-478.","journal-title":"Oncol Rep"},{"key":"3565_CR27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger M, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the signal transduction inhibitor STI571: diverse mechanisms of resistance. Blood. 2000, 96: 1070-1079.","journal-title":"Blood"},{"key":"3565_CR28","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","volume":"52","author":"C Tang","year":"2011","unstructured":"Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP: Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma. 2011, 52: 2139-2147. 10.3109\/10428194.2011.591013.","journal-title":"Leuk Lymphoma"},{"key":"3565_CR29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cellsig.2011.02.005","volume":"23","author":"O Yamada","year":"2011","unstructured":"Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R: Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal. 2011, 23: 1119-1127. 10.1016\/j.cellsig.2011.02.005.","journal-title":"Cell Signal"},{"key":"3565_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1477-5956-10-23","volume":"10","author":"S Corr\u00eaa","year":"2012","unstructured":"Corr\u00eaa S, Pizzatti L, Du Rocher B, Mencalha A, Pinto D, Abdelhay E: A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line. Proteome Sci. 2012, 10: 23-10.1186\/1477-5956-10-23. Epub ahead of print","journal-title":"Proteome Sci"},{"key":"3565_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","volume":"73","author":"VM Rumjanek","year":"2001","unstructured":"Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA: Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc. 2001, 73: 57-69. 10.1590\/S0001-37652001000100007.","journal-title":"An Acad Bras Cienc"},{"key":"3565_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/BJ20050327","volume":"393","author":"R Binato","year":"2006","unstructured":"Binato R, Alvarez Martinez CE, Pizzatti L, Robert B, Abdelhay E: SMAD 8 binding to mice Msx1 basal promoter is required for transcriptional activation. Biochem J. 2006, 393: 141-150. 10.1042\/BJ20050327.","journal-title":"Biochem J"},{"key":"3565_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/gcc.20722","volume":"49","author":"L Pizzatti","year":"2010","unstructured":"Pizzatti L, Binato R, Cofre J, Gomes BE, Dobbin J, Haussmann ME, D'Azambuja D, Bouzas LF, Abdelhay E: SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia. Genes Chromosomes Cancer. 2010, 49: 107-118.","journal-title":"Genes Chromosomes Cancer"},{"key":"3565_CR34","volume-title":"Cold Spring Harb. Protoc","author":"A Wagschal","year":"2007","unstructured":"Wagschal A, Delaval K, Pannetier M, Arnaud P, Feil R: Chromatin Immunoprecipitation (ChIP) on Unfixed Chromatin from Cells and Tissues to Analyze Histone Modifications. Cold Spring Harb. Protoc. 2007"},{"key":"3565_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C (T)) Method. Methods. 2001, 25: 402-408. 10.1006\/meth.2001.1262.","journal-title":"Methods"},{"key":"3565_CR36","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0960-9822(02)70790-2","volume":"6","author":"V Stambolic","year":"1996","unstructured":"Stambolic V, Ruel L, Woodgett JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996, 6: 1664-1668. 10.1016\/S0960-9822(02)70790-2.","journal-title":"Curr Biol"},{"key":"3565_CR37","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1471-4159.2008.05537.x","volume":"106","author":"JC Lim","year":"2008","unstructured":"Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, Romero IA, Couraud PO, Weksler BB, Hladky SB, Barrand MA: Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008, 106: 1855-1865.","journal-title":"J Neurochem"},{"key":"3565_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7: 441-453. 10.1038\/nrc2147.","journal-title":"Nat Rev Cancer"},{"key":"3565_CR39","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T: Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010, 120: 2254-2264. 10.1172\/JCI41246.","journal-title":"J Clin Invest"},{"key":"3565_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.beha.2009.09.002","volume":"22","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Fava C, Kantarjian H: Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Prac Res Clin Haematol. 2009, 22: 395-407. 10.1016\/j.beha.2009.09.002.","journal-title":"Best Prac Res Clin Haematol"},{"key":"3565_CR41","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.3816\/CLM.2007.s.011","volume":"7","author":"R Swords","year":"2007","unstructured":"Swords R, Alvarado Y, Giles F: Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma. 2007, 7: S113-S119.","journal-title":"Clin Lymphoma Myeloma"},{"key":"3565_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","volume":"25","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury S, Talpaz M: Managing resistance in chronic myeloid leukemia. Blood Reviews. 2011, 25: 279-290. 10.1016\/j.blre.2011.09.001.","journal-title":"Blood Reviews"},{"key":"3565_CR43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","volume":"1587","author":"T Hegedus","year":"2002","unstructured":"Hegedus T, Orfi L, Seprodi A, V\u00e1radi A, Sarkadi B, K\u00e9ri G: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta. 2002, 1587: 318-325. 10.1016\/S0925-4439(02)00095-9.","journal-title":"Biochim Biophys Acta"},{"key":"3565_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1124\/jpet.103.055574","volume":"307","author":"A Hamada","year":"2003","unstructured":"Hamada A, Miyano H, Watanabe H, Saito H: Interaction of Imatinib Mesilate with Human P-Glycoprotein. J Pharmacol Exp Ther. 2003, 307: 824-828. 10.1124\/jpet.103.055574.","journal-title":"J Pharmacol Exp Ther"},{"key":"3565_CR45","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"FX Mahon","year":"2003","unstructured":"Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003, 101: 2368-2373. 10.1182\/blood.V101.6.2368.","journal-title":"Blood"},{"key":"3565_CR46","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004, 351: 657-667. 10.1056\/NEJMoa040258.","journal-title":"N Engl J Med"},{"key":"3565_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","volume":"18","author":"MA Gregory","year":"2010","unstructured":"Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J: Wnt\/Ca2+\/NFAT signaling maintains survival of Ph\u2009+\u2009leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010, 18: 74-87. 10.1016\/j.ccr.2010.04.025.","journal-title":"Cancer Cell"},{"key":"3565_CR48","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","volume":"26","author":"AM Coluccia","year":"2007","unstructured":"Coluccia AM, Vacca A, Du\u00f1ach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C: Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007, 26: 1456-1466. 10.1038\/sj.emboj.7601485.","journal-title":"EMBO J"},{"key":"3565_CR49","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.embor.7400536","volume":"11","author":"A Ress","year":"2005","unstructured":"Ress A, Moelling K: Bcr is a negative regulator of the Wnt signalling pathway. EMBO Reports. 2005, 11: 1095-1100.","journal-title":"EMBO Reports"},{"key":"3565_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11899-012-0121-6","volume":"7","author":"LA Crews","year":"2012","unstructured":"Crews LA, Jamieson CH: Chronic Myeloid Leukemia Stem Cell Biology. Curr Hematol Malig Rep. 2012, 7: 125-132. 10.1007\/s11899-012-0121-6.","journal-title":"Curr Hematol Malig Rep"},{"key":"3565_CR51","doi-asserted-by":"publisher","first-page":"713","DOI":"10.18632\/oncotarget.333","volume":"2","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Turhan AG: Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011, 2: 713-727.","journal-title":"Oncotarget"},{"key":"3565_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3747\/co.v18i4.652","volume":"18","author":"B Leber","year":"2011","unstructured":"Leber B: CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure. Curr Oncol. 2011, 18: 185-190.","journal-title":"Curr Oncol"},{"key":"3565_CR53","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F, Turhan AG: Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011, 118: 3657-3660. 10.1182\/blood-2011-02-335497.","journal-title":"Blood"},{"key":"3565_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11899-010-0043-0","volume":"5","author":"GV Helgason","year":"2010","unstructured":"Helgason GV, Young GA, Holyoake TL: Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep. 2010, 5: 81-87. 10.1007\/s11899-010-0043-0.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-303\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T11:18:24Z","timestamp":1714216704000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,23]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3565"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-303","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,23]]},"assertion":[{"value":"27 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"303"}}